gdc
Breast CancerFDA Approvals, News & UpdatesNewsworthy

Verzenio a New Targeted Therapy Approved for Metastatic Breast Cancer

Read about Verzenio, which was approved by the FDA in 2017, in combination with fulvestrant, for treatment of women with HR-positive, HER2-positive, HER2-negative advanced, or metastatic breast cancer that progressed after endocrine therapy.
December 2017 Vol 3 No 6

On September 28, 2017, the FDA approved Verzenio (abemaciclib; from Eli Lilly), a CDK4/CDK6 inhibitor, in combination with fulvestrant, for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy, as well as for use alone in patients whose metastatic breast cancer progressed after endocrine therapy and after previous use of chemotherapy in the metastatic setting.

“Verzenio provides a new targeted treatment option for certain patients with breast cancer who are not responding to treatment, and unlike other drugs in the class, it can be given as a stand-alone treatment to patients who were previously treated with endocrine therapy and chemotherapy,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The FDA approved Verzenio for these 2 uses based on clinical trials showing its benefits for patients with HR-positive, HER2-negative advanced or metastatic breast cancer. The most common side effects with Verzenio are diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, and thrombocytopenia.

Share this:

Recommended For You
Endometrial CancerFDA Approvals, News & UpdatesImmunotherapy
Jemperli First Immunotherapy FDA Approved for Endometrial Cancer with dMMR Biomarker
In April 2021, the FDA approved Jemperli (dostarlimab-gxly) for patients with recurrent or advanced endometrial cancer and the biomarker mismatch repair-deficient. This is the first immunotherapy approved for patients with this type of cancer.
FDA Approvals, News & UpdatesGastric CancerImmunotherapy
Opdivo First Immunotherapy Approved for First-Line Therapy of Gastric Cancers
In April 2021, the FDA approved Opdivo (nivolumab), for use with chemotherapy, as first-line treatment for patients with advanced or metastatic gastric cancer, including gastroesophageal junction cancer and esophageal adenocarcinoma.
FDA Approvals, News & UpdatesGastric CancerImmunotherapy
Keytruda Another Immunotherapy Approved for First-Line Treatment of Advanced Gastric Cancer
In May 2021, the FDA approved Keytruda (pembrolizumab), plus Herceptin and chemotherapy, for first-line treatment of locally advanced unresectable or metastatic, HER2-positive gastric or gastroesophageal junction adenocarcinoma. Keytruda is the second immunotherapy approved for gastric cancer.
Breast CancerCONQUER CamFamily MembersPatient Stories
CONQUER Cam: A Spotlight on Sara Olsher
By Sara Olsher
Sara Olsher was diagnosed with breast cancer at 34 years old. Explaining her diagnosis to her 6-year-old daughter and parenting through her treatment proved to be difficult. To help families like hers, Sara founded Mighty + Bright, which provides resources for families going through hard times, and wrote and illustrated the children’s book, “Someone I Love Has Cancer.”
Last modified: March 25, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest